Hidden Operating Room Allergens: Dyes, Implants, Chlorhexidine Overwash

Underrecognized Exposures Complicate the Workup

 often traces back to agents that never make it into the medical record. Kimberly Blumenthal, MD, MSc, a professor of medicine at the Mayo Clinic College of Medicine and Science, told 

 that surgical dyes, antibiotic-coated implantable devices, and latex exposure from a surgeon's gloves or an all-latex operating room are all potential culprits that are inconsistently documented, leaving allergists to reconstruct exposures after the fact.

Blumenthal singled out chlorhexidine gluconate, the disinfectant used to clean the skin before incision, as an emerging cause of perioperative anaphylaxis. She noted that patients are sometimes instructed to wash with chlorhexidine for several days before surgery and are washed again on arrival, a repeated-exposure pattern that can sensitize patients before they ever reach the operating room. A recent case report similarly describes chlorhexidine as increasingly recognized as a perioperative anaphylaxis trigger capable of producing both immediate and delayed hypersensitivity reactions after repeated antiseptic exposure.¹

The OR Is a Controlled Setting for Treatment

Once anaphylaxis is recognized, Blumenthal said the operating room is one of the safer places for it to occur.

“It's the safest place to have anaphylaxis,” she said. “Maybe the allergist office is equally safe, but the anesthesia room patients are either already intubated or can be intubated, so they can have their airway protected. They have lines…of access intravenously to be able to administer medications. Once it's detected, the treatment is very easy…because they have access to all the medicines that are needed.”

The anesthesia team has immediate access to epinephrine and vasopressors such as norepinephrine and phenylephrine, steroids, and antihistamines.

The harder problem is recognition. Blumenthal explained that surgical drapes can hide a rash, and hypotension has a broad differential that includes routine medication side effects rather than allergy. A recent narrative review of perioperative anaphylaxis echoed this diagnostic challenge, noting that cutaneous findings may be absent, delayed, or concealed by drapes while hypotension, bronchospasm, and desaturation can stem from multiple causes occurring within minutes of each other.² Even when treatment goes smoothly, a reaction typically forces the procedure to be rescheduled.

Counseling Patients Without a Confirmed Culprit

When testing fails to identify a cause, Blumenthal said allergists rely on what negative results are available. Negative skin tests to specific agents support using those drugs again, ideally with a test dose that introduces a small amount first, followed by observation before the remaining dose is given.

Where no culprit is confirmed, Blumenthal said allergists can still recommend an alternative agent based on which exposure seems statistically or clinically most likely, such as switching neuromuscular blocking agents to succinylcholine. She said this guidance, while imperfect, generally allows patients to proceed through subsequent surgeries safely.

Read part 1 of our interview with Blumenthal on common triggers of perioperative anaphylaxis here: 

What's Behind Perioperative Anaphylaxis? Cefazolin Tops the List

Sandoval Morales F, Pelletier F, Aubin F, Castelain F. Chlorhexidine-Induced Contact Anaphylaxis. 

Perioperative anaphylaxis: preparing for the next rocuronium, chlorhexidine, or antibiotic reaction. GlobalRPH. Published 2026. 

https://globalrph.com/2026/07/perioperative-anaphylaxis-preparing-for-the-next-rocuronium-chlorhexidine-or-antibiotic-reaction/

Videos

Kimberly Blumenthal, MD, MSc, explains how surgical dyes, antibiotic-coated implants, and more can trigger perioperative anaphylaxis without appearing in the chart.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

Sanjay Rajagopalan, MD, is the chief academic and scientific officer at University Hospitals Case Medical Center.

Improving Air Quality Indices for Personalized Health Warnings from Pollution Exposure

A recent response to the World Health Organization (WHO) State of Global Air 2025 report has indicated the critical need for direct associations between air quality and 

“This was a commentary on the World Health Organization roadmap for air quality, and the driver for this was the recognition that most air quality indices that inform the public are not really linked to health outcomes,” Sanjay Rajagopalan, MD, the chief academic and scientific officer at University Hospitals Case Medical Center and a co-author of the publication, told 

 in an exclusive interview. “In other words, they don’t provide you with an indicator of what the air quality might do to actual health outcomes, and that’s an important inefficiency.”

Air pollution ranks as the second leading risk factor for death worldwide – in 2023, pollution exposure accounted for roughly 8 million deaths. Almost all populated areas in the world do not meet WHO air quality targets due to fine particulate matter, or particles with a diameter ≤2.5 µm, also known as PM

. This particle directly contributes to cardiovascular, metabolic, neurologic, and respiratory diseases.

Although most mortality is a result of long-term PM

 exposure, Rajagopalan notes that a significant proportion of annual deaths is attributed to short-term exposures lasting a few days or less. To protect individuals from accidental exposure during short-term increases in air pollution, such as wildfire smoke, the US regularly releases daily values from local air-quality indices (AQIs).

To this end, the WHO released its January 2026 report, an evaluation of AQI tools to ensure their alignment with the latest scientific evidence. In the document, the organization distinguished 2 broader categories of AQIs: conventional AQIs, which break down short-term pollutant concentrations with standardized, unitless scales, and air-quality health indices (AQHIs), which provide values indicative of health risks associated with exposures to mixtures of pollutants like PM

AQHIs calculate risk estimates via regression analyses from country-specific, short-term epidemiologic studies. In addition to collating all health risks into a single value, AQHIs work to communicate the risks associated with exposure to air pollution more accurately than standard AQIs. Cited by the WHO as a prime example, Canada’s 2008 AQHI, updated recently for increasingly prevalent wildfire smoke, could potentially drive further AQHI development for individual countries or geographic areas.

While the WHO report provides a framework for evaluating AQIs in multiple aspects, Rajagopalan and colleagues note that the models typically rely on a one-size-fits-all risk-communication strategy, which limits their actionability on an individual basis. Disparities in health literacy, linguistic diversity, and occupational realities can skew the effectiveness of both AQIs and AQHIs on certain patient populations.

To that end, Rajagopalan and colleagues encourage further research to enhance both the design and effectiveness of these models. Additionally, their implementation into clinical care may provide patients a more nuanced and direct interaction with the warning models, allowing them to receive direct and personalized suggestions for their individual conditions.

“I completely refute the idea that environmental factors are non-actionable, that there are things you can’t do anything about,” Rajagopalan said. “There are things we can do as a community to bring forth these very important connections between individual health, population health, and planetary health.”

Editors’ Note: Rajagopalan reports disclosures with Bayer Healthcare and Novo Nordisk.

Brook RD, Rajagopalan S. Improving Global Air-Quality Indices — the WHO’s New Roadmap. 

State of global air 2025: a report on air pollution and its role in the world’s leading causes of death. Boston: Health Effects Institute, 2025 

https://www.stateofglobalair.org/resources/report/state-global-air-report-2025

Sanjay Rajagopalan, MD, discusses the need for more patient-specific air pollution warnings to optimize accessibility for all individuals.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Marc Richards, MD is a nephrologist at Florida Kidney Physicians, LLC and Director of the FKP Glomerulonephritis Center of Excellence in Boca Raton, Florida.

centered largely on controlling blood pressure, managing diabetes, and using renin-angiotensin system blockade when appropriate. Today, that approach has expanded considerably, with a growing number of disease-modifying therapies targeting distinct pathways involved in kidney injury and progression.

CKD affects more than 1 in 7 US adults, yet many patients remain unaware they have the disease, underscoring the need for earlier recognition and more effective treatment strategies.

The emergence of sodium-glucose cotransporter 2 (SGLT2) inhibitors, nonsteroidal mineralocorticoid receptor antagonists, and other therapies has transformed the clinical approach to slowing CKD progression.

, Marc Richards, MD, a nephrologist at Florida Kidney Physicians, discusses how this expanding evidence base is changing CKD management, the role of combination therapy, and why clinicians should continue adopting new treatment strategies.

Q&A: Expanding Era of Evidence-Based CKD Care, With Marc Richards, MD

When you're thinking about managing chronic kidney disease in 2026, what do you consider the essential components of evidence-based care?

Richards: I think what's amazing is that we actually have evidence-based care now. Up until a few years ago, it was, you know, maybe take care of your blood pressure, take care of your blood sugar, maybe take an ACE inhibitor, and avoid medicines that are bad for the kidneys. And really, outside of that, there was nothing we could really tell patients.

But now our data is exploding. We have evidence with ACE inhibitors and ARBs for proteinuric kidney disease states. We have SGLT2 inhibitors becoming a standard of care. We now have the nonsteroidal MRAs that are on the market, both in diabetic and—now we're learning—non-diabetic kidney disease, that could benefit our patients. Data is emerging with GLP‑1 agonists.

Also, nephrology is teeming with these new clinical trials that can help us really get more medicines to the forefront and have a really good evidence base to manage our patients.

As you’ve mentioned, there are so many new therapies that have emerged in recent years that target very different pathways. How has that shifted your thinking about combination therapy or selecting treatments for individual patients?

Richards: We like that there was the CONFIDENCE trial, which was really recent, where they looked at combining SGLT2 inhibitors with finerenone, which is the nonsteroidal mineralocorticoid receptor antagonist. They showed that you got pretty good reduction in proteinuria with either of those agents, but when you use them together, you actually had a synergistic effect and the protein in the urine got even better.

I think sometimes patients might get a little frustrated when we're adding medicine on top of medicine, but if you explain that they all work together from different angles to protect kidneys, the patients are willing to accept combination therapy.

I don't know if that answered your question totally about the individualized care, but certainly if a patient does have protein in the urine, that would make me more willing to be more aggressive with that type of therapy.

: If every nephrologist listening today could make one change in their practice tomorrow, what would you want it to be?

Richards: I really think it's being earlier adopters of this evidence. I think a lot of nephrologists have been sort of swayed to sleep by 20 to 25 years of really no groundbreaking developments in how we manage chronic kidney disease.

We've gone from that to now potentially three new classes of agents on the market, and potentially more, that can delay progression of kidney disease in our patients and prevent progression to end-stage kidney disease.

So I think we just need to wake up and realize that we have this great evidence out there. We have new classes of agents out there that are readily available to use on our patients, and we can really make a difference in the lives of our patients.

Was there anything else that I didn't ask about that you think you would want to highlight or add?

Richards: I think the only other thing would be that in addition to what we now have, we always have the potential for more. At least our practice, and a lot of academic and private practices throughout the country, are very active with clinical research.

Potentially the next great treatment is out there, but we just need to get patients into clinical trials to see if we can establish new standards of care to optimize management of our patients.

Editor’s Note: Richards reports no relevant disclosures.

National Institute of Diabetes and Digestive and Kidney Diseases. 

Kidney Disease Statistics for the United States

https://www.niddk.nih.gov/health-information/health-statistics/kidney-disease

Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. 

. 2020;383(15):1436-1446. doi:10.1056/NEJMoa2024816.

Articles

Chronic kidney disease care has shifted from largely supportive management—blood pressure and glycemic control, ACE inhibitor/ARB use in proteinuric disease, and avoidance of nephrotoxins—to a rapidly expanding, evidence-based, disease-modifying paradigm. With CKD affecting more than 1 in 7 US adults and substantial under-recognition, earlier detection and timely initiation of kidney-protective agents are increasingly critical. SGLT2 inhibitors have become foundational, nonsteroidal mineralocorticoid receptor antagonists are gaining broader applicability beyond diabetes, and GLP‑1 agonist data are emerging alongside robust trial activity.

Marc Richards, MD, discusses how new therapies and combination treatment strategies are transforming evidence-based care for chronic kidney disease.


Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

Strategic Alliance Partnership

Expanding Era of Evidence-Based CKD Care, With Marc Richards, MD

Giovanni Leone, MD, from Israelite Hospital.

Oral GP-SOD for Vitiligo: Safety Profile, Dosing, and What's Next

 receiving oral gliadin-protected superoxide dismutase (GP-SOD) alongside targeted excimer phototherapy showed significantly greater improvement in both repigmentation and quality of life than those on phototherapy alone at 6 months.

The 6-month, single-center trial enrolled 40 patients with localized non-segmental vitiligo, randomly assigning half to add oral GP-SOD to excimer lamp treatment. Mean VASI improvement was -1.65 in the combination group versus -1.14 with phototherapy alone, a significant between-group difference (mean difference 0.51; 95% CI, 0.28-0.74; 

 Quality-of-life scores, measured with VitiQoL, also improved significantly more in the combination group, with a between-group difference of 5.59 (95% CI, 4.01-7.17;

, Giovanni Leone, MD, of the Photodermatology and Vitiligo Treatment Center at Israelite Hospital, discussed the safety findings behind those results, including why the combination group saw less treatment-related erythema, his recommended dosing protocol, and where he sees the research heading next.

Leone recommends 2 capsules of GP-SOD before breakfast and 2 before lunch, for a total of 4 capsules daily. He advised against evening dosing, noting that some patients reported insomnia when taking the supplement later in the day. Aside from that adjustment, he said tolerability has been consistently high.

Why Erythema Was Less Frequent With GP-SOD

Leone said GP-SOD itself produced no reported adverse events in the trial. The only adverse events were cases of erythema from the excimer lamp, a known effect of phototherapy.

He said the lower erythema rate in the combination group likely reflects a systemic photoprotective effect of antioxidants beyond their action on melanocyte-damaging mechanisms. Antioxidants are used clinically to build UV resistance even in patients without vitiligo, he said, which may explain the reduced erythema seen with GP-SOD.

Contraindications for GP-SOD and Phototherapy

Celiac disease or gluten hypersensitivity is an absolute contraindication to GP-SOD, Leone said, since the compound is gluten-based. Beyond that, he said exclusion criteria follow standard phototherapy contraindications: a family history of skin cancer or melanoma, UV-sensitive skin, and photodermatoses.

Next Steps: Polymorphic Light Eruption and New Protocols

Leone said his group is now exploring GP-SOD's photoprotective properties as a potential treatment or preventive strategy for polymorphic light eruption, a common sun-triggered photodermatosis. He said additional vitiligo protocol variations are also under consideration, though the current regimen remains his preferred approach for now.

“The most important message is that this treatment is…well tolerated, contributes to lower the risks of long-term phototherapy in terms of shortening the treatment period, [and] is very well accepted by the patients,” Leone said. “The rapidity of the treatment…make it a very good option. Without using very expensive and complicated drugs, we have a good result.”

Watch part 1 of our interview with Leone here: 

Oral GP-SOD Plus Targeted Phototherapy Boosts Vitiligo Repigmentation

Leone G, Bertold C, Vidolin AP, Fontas E, Passeron T. Combination of Oral Gliadin-Protected Superoxide Dismutase With Targeted Phototherapy in Vitiligo: A Prospective, Comparative, Randomized, Single-Blinded Study. 

Leone G. Oral GP-SOD Plus Targeted Phototherapy Boosts Vitiligo Repigmentation. HCPLive. Published on July 14, 2026. Accessed July 17, 2026. 

https://www.hcplive.com/view/oral-gp-sod-plus-targeted-phototherapy-vitiligo-repigmentation

Erythema was less frequent with combination therapy than with phototherapy alone, according to Giovanni Leone, MD.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Vitiligo

Vitiligo condition center page is a comprehensive resource for clinical news and insights on the dermatologic condition. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for the affected skin of vitiligo patients.

Ann Marie Navar, MD, PhD, is an associate professor of cardiology at the University of Texas Southwestern Medical Center.

Enlicitide Receives FDA Approval for Hypercholesterolemia Following CORALreef Trials

 has officially approved the first-ever oral PCSK9 inhibitor, enlicitide, for the reduction of LDL-C in adult patients with 

Parent company Merck announced the approval on July 16, 2026, which followed positive data from the CORALreef Lipids and CORALreef HeFH trials. Enlicitide, approved under the name Lipfendra, substantially reduced LDL-C in both trials compared to placebo. The drug is administered in the form of 20 mg tablets as an adjunct to diet and exercise and has been approved for patients with heterozygous familial hypercholesterolemia (HeFH) in addition to hypercholesterolemia.

“This is really big,” Ann Marie Navar, MD, PhD, associate professor of medicine in the Division of Cardiology at UT Southwestern Medical Center, told 

 in an exclusive interview. “We now have an oral option that lowers LDL cholesterol by up to 60% on top of high-intensity statins and other background therapies. That’s huge in terms of getting more patients to goal.”

CORALreef Lipids was a multinational, double-blind, randomized, placebo-controlled trial including patients with a history of major 

atherosclerotic cardiovascular disease (ASCVD)

 events with an LDL-C level of ≥55 mg/dL or those who were at risk of a first ASCVD event with an LDL-C ≥70 mg/dL. These patients were assigned in a 2:1 ratio to receive either 20 mg enlicitide or placebo daily for 52 weeks.

The primary endpoint for CORALreef Lipids was mean percent change in LDL-C level from baseline to week 24. Secondary endpoints included mean percent LDL-C level changes at week 52 and mean percent change in non-HDL-C, apolipoprotein B (apoB), and lipoprotein(a) levels at week 24.

A total of 2909 patients were enrolled in CORALreef Lipids, of whom 1935 received enlicitide and 969 received placebo. Mean LDL-C level at baseline was 96.1 +/- 38.9 mg/dL, while mean percent change by week 24 was -57.1% (95% CI, -61.8 to -52.5) with enlicitide and 3% (95% CI, 0.9 to 5.1) with placebo. This represented an adjusted between-group difference of -55.8% (95% CI, -60.9 to -50.7; 

 <.001). The percent change in LDL-C at week 52, as well as the changes in Lp(a), non-HDL-C, and apoB at week 24, were all greater with enlicitide than placebo.

The CORALreef HeFH trial included patients ≥18 years old with HeFH who were actively using lipid-lowering therapy – either a moderate- or high-intensity statin – and who had an LDL-C level ≥55 mg/dL with a history of major ASCVD or an LDL-C level ≥70 mg/dL without a history of major ASCVD.

Participants were randomly assigned in a 2:1 ratio to receive either 20 mg of enlicitide or placebo once daily for 52 weeks. The primary outcome for CORALreef HeFH was the same as in CORALreef Lipids, while secondary endpoints included the same measurements of apoB and non-HDL-C, as well as percent change in LDL-C at week 52.

A total of 303 patients were enrolled and randomized, with 202 receiving enlicitide and 101 receiving placebo. Mean LDL-C at baseline was 119 mg/dL (standard deviation [SD], 41 mg/dL). Mean percentage change at week 24 in LDL-C was -58.2% in the enlicitide group versus 2.6% in the placebo group, with a between-group difference of -59.4% (95% CI, -65.6% to -53.2%; 

 <.001). The mean percentage change in LDL-C at week 52 was -55.3% in the enlicitide group versus 8.7% in the placebo group, with a between-group difference of -61.5% (95% CI, -69.4% to -53.7%; 

While the approval itself was based on the positive results from these 2 trials, Merck has also launched the ongoing CORALreef Outcomes study, which is examining the effects of enlicitide on cardiovascular morbidity and mortality over the long term.

“This approval is just the first step,” Navar said. “Now we actually have to get it into the hands of our clinician prescribers, and then ultimately into our patients. It’s going to come down to: are people going to use it, and are we going to be able to get payers and insurers to cover it for the patients that need it?”

Editors’ Note: Navar reports disclosures with Esperion Therapeutics, Bristol Myers Squibb, Amgen, Janssen Pharmaceuticals, Eli Lilly, Novo Nordisk, and others.

Merck. Merck’s LIPFENDRA (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the US FDA to Reduce LDL-C in Adults with Hypercholesterolemia. July 16, 2026. July 17, 2026. 

https://www.merck.com/news/mercks-lipfendra-enlicitide-is-the-first-and-only-once-daily-oral-pcsk9-inhibitor-approved-by-the-u-s-fda-to-reduce-ldl-c-in-adults-with-hypercholesterolemia/

Navar AM, Mikhailova E, Catapano AL, et al. A placebo-controlled trial of the oral PCSK9 inhibitor enlicitide. 

Ballantyne CM, Gellis L, Tardif J-C, et al. Efficacy and safety of oral PCSK9 inhibitor enlicitide in adults with heterozygous familial hypercholesterolemia. 

Ann Marie Navar, MD, PhD, discusses the groundbreaking approval of the first oral PCSK9 inhibitor and what it means for patients managing their LDL-C levels.

FDA News

Dyslipidemia

Atherosclerotic Cardiovascular Disease

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

FDA accepted Camurus’ resubmitted CAM2029 application for acromegaly, with a target action date of December 18, 2026.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

This page also hosts content previously published by EndocrinologyNetwork. 


Hormonal Disorders

FDA Accepts Resubmitted CAM2029 NDA for Acromegaly

Michael Richards, MD, discusses aldosterone's role in CKD pathophysiology and why targeting this pathway may reshape kidney disease treatment.

Why Aldosterone Has Become a Key Target in CKD Care, With Marc Richards, MD

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

The FDA granted traditional approval to Novartis’ iptacopan (Fabhalta) for adults with primary IgA nephropathy, supported by phase 3 APPLAUSE-IgAN data showing slowed kidney function decline and sustained proteinuria reductions.

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

FDA Grants Full Approval to Iptacopan (Fabhalta) in IgAN

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

New secondary endpoint analyses from Phase 3 LATITUDE PsO 3001 and 3002 reveal high rates of clearance on high-impact areas.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Zasocitinib: High Rates of Clearance for Scalp, Nail, Palmoplantar PsO

Boadie Dunlop, MSC, professor and chair of psychiatry and health behavior at the Medical College of Georgia at Augusta University.

Boadie Dunlop, MD, discusses COMP360 dosing-day monitoring, treatment resistance, and where psilocybin may fit among existing TRD options.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

COMP360 Psilocybin for TRD: What to Know Before a Possible 2027 Launch 

A recent analysis of data from the Global Burden of Disease Study has indicated a relationship between risk of death from ACHD and socioeconomic factors.

Structural Heart Disease

ACHD Mortality Displays Correlation With Lower Household Income, Lack of Insurance

Thanai Pongdee, MD, discusses 4-year PIONEER data showing avapritinib's quality of life, symptom, and safety benefits in indolent systemic mastocytosis remain durable.

Avapritinib 4-Year Data Show Durable Quality of Life Gains in ISM

Allan B. Massie, PhD, is an associate professor in the Department of Surgery and an associate professor in the Department of Population Health at NYU Langone.

NYU Langone’s Conor Donnelly, Allan Massie, and Michal Mankowski explain why follow-up after kidney transplant referral is critical to improving access.

Don’t Forget to Follow Up After Kidney Transplant Referral

Patrick Campbell is the editorial director of HCPLive. Patrick has spent years spearheading coverage surrounding cardiometabolic health and rheumatic disease for MJH Life Sciences. Before joining MJH Life Sciences in 2019, he spent time as a beat reporter and/or multimedia specialist with the Pocono Record, Star News Group, and NJ Advance Media. He is the executive producer for multiple HCPLive podcasts, including Diabetes Dialogue, Don't Miss a Beat, Kidney Compass, Medical Ethics Unpacked, The Medical Sisterhood, and Skin of Color Savvy. 


Follow him on Twitter @RealPatCampbell or reach him via email at PCampbell@mjhlifesciences.com.

A multidisciplinary clinical forum discussed diagnosis, referral thresholds, and the evolving APOC3-targeted treatment landscape for FCS.

Diagnosing and Treating Familial Chylomicronemia Syndrome: Perspectives from a Clinical Forum

Dr. Martin is an assistant professor at the Ciccarone Center for the Prevention of Heart Disease at the Johns Hopkins University School of Medicine.

Seth Martin, MD, MHS, discusses his recent study, which produced an AI-optimized equation that only requires 1 line of code.

Latest News

Hidden Operating Room Allergens: Dyes, Implants, Chlorhexidine Overwash

Improving Air Quality Indices for Personalized Health Warnings from Pollution Exposure

Expanding Era of Evidence-Based CKD Care, With Marc Richards, MD

Oral GP-SOD for Vitiligo: Safety Profile, Dosing, and What's Next

Enlicitide Receives FDA Approval for Hypercholesterolemia Following CORALreef Trials